SPRB Profile
Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to advancing novel therapies for rare endocrine disorders. The company focuses on developing treatments that address unmet needs in the management of complex and infrequently encountered conditions. Its primary product candidate, tildacerfont, represents a significant innovation in the field, offering a non-steroidal approach aimed at improving disease control while minimizing the reliance on steroid medications.
Tildacerfont is currently undergoing multiple Phase 2b clinical trials. The therapy is being evaluated for its efficacy in reducing the steroid burden and improving disease management in adult patients with congenital adrenal hyperplasia (CAH), a rare genetic disorder affecting adrenal hormone production. The trials aim to assess the drug’s ability to reduce glucocorticoid use and its overall impact on clinical outcomes in patients with classic CAH.
Additionally, Spruce Biosciences is advancing tildacerfont through Phase 2 clinical trials for the treatment of pediatric patients with classic congenital adrenal hyperplasia. This research is focused on evaluating the drug’s effectiveness and safety in younger populations. The company is also exploring the use of tildacerfont for females with polycystic ovary syndrome (PCOS), another condition where its therapeutic potential is being assessed in a Phase 2 trial.
Established in 2014 and headquartered in Daly City, California, Spruce Biosciences has forged a strategic license agreement with Eli Lilly and Company. This collaboration enables Spruce Biosciences to leverage Eli Lilly's extensive resources and expertise to research, develop, and commercialize new compounds for various pharmaceutical applications. The company’s commitment to addressing rare endocrine disorders positions it as a key innovator in the biopharmaceutical industry.
|
